Citations (63)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
VI Seledtsov, AG Goncharov & GV Seledtsova. (2015) Clinically feasible approaches to potentiating cancer cell-based immunotherapies. Human Vaccines & Immunotherapeutics 11:4, pages 851-869.
Read now
Read now
Thomas Meyer, Christian Surber, Lars E French & Eggert Stockfleth. (2013)
Resiquimod, a topical drug for viral skin lesions and skin cancer. Expert Opinion on Investigational Drugs 22:1, pages 149-159.
Read now
Read now
Faezeh Moghimpour Bijani, Jesus G. Vallejo & Nima Rezaei. (2012) Toll-like Receptor Signaling Pathways in Cardiovascular Diseases: Challenges and Opportunities. International Reviews of Immunology 31:5, pages 379-395.
Read now
Read now
Namrata Iyer, Sandhya A. Marathe, Debalina Chaudhuri, Preeti Garai & Dipshikha Chakravortty. (2012) Immunomodulation using agonists and antagonists: potential clinical applications. Expert Opinion on Investigational Drugs 21:1, pages 67-81.
Read now
Read now
Cheryl Lai-Lai Chiang, Lana E. Kandalaft & George Coukos. (2011) Adjuvants for Enhancing the Immunogenicity of Whole Tumor Cell Vaccines. International Reviews of Immunology 30:2-3, pages 150-182.
Read now
Read now
Manoli Igartua & José Luís Pedraz. (2010) Topical resiquimod: a promising adjuvant for vaccine development?. Expert Review of Vaccines 9:1, pages 23-27.
Read now
Read now
Amani Makkouk & Alexander M. Abdelnoor. (2009) The potential use of toll-like receptor (TLR) agonists and antagonists as prophylactic and/or therapeutic agents. Immunopharmacology and Immunotoxicology 31:3, pages 331-338.
Read now
Read now
Articles from other publishers (56)
Veronica Folliero, Federica Dell’Annunziata, Annalisa Chianese, Maria Morone, Francesca Mensitieri, Federica Di Spirito, Antonio Mollo, Massimo Amato, Massimiliano Galdiero, Fabrizio Dal Piaz, Pasquale Pagliano, Luca Rinaldi & Gianluigi Franci. (2023) Epigenetic and Genetic Keys to Fight HPV-Related Cancers. Cancers 15:23, pages 5583.
Crossref
Crossref
Run Zheng & Jian Ma. (2022) Immunotherapeutic Implications of Toll-like Receptors Activation in Tumor Microenvironment. Pharmaceutics 14:11, pages 2285.
Crossref
Crossref
Flora W. Kimani, Saikat Manna, Brittany Moser, Jingjing Shen, Naorem Nihesh & Aaron P. Esser-Kahn. (2021) Improving the Adjuvanticity of Small Molecule Immune Potentiators Using Covalently Linked NF-κB Modulators. ACS Medicinal Chemistry Letters 12:9, pages 1441-1448.
Crossref
Crossref
Deepender Kaushik, Juliana T Granato, Gilson C Macedo, Paula R B Dib, Sakshi Piplani, Johnson Fung, Adilson D da Silva, Elaine S Coimbra, Nikolai Petrovsky & Deepak B Salunke. (2021)
Toll-like receptor-7/8 agonist kill
Leishmania amazonensis
by acting as pro-oxidant and pro-inflammatory agent
. Journal of Pharmacy and Pharmacology 73:9, pages 1180-1190.
Crossref
Crossref
Anindya Sarkar, Anushka C. Galasiti Kankanamalage, Qian Zhang, Heng Cheng, Prasanna Sivaprakasam, Joseph Naglich, Chunshan Xie, Sanjeev Gangwar & Dale L. Boger. (2021) Synthesis, structure-activity relationship studies and evaluation of a TLR 3/8/9 agonist and its analogues. Medicinal Chemistry Research 30:7, pages 1377-1385.
Crossref
Crossref
Dina V. Hingorani, Maria F. Camargo, Maryam A. Quraishi, Stephen R. Adams & Sunil J. Advani. (2021) Tumor Activated Cell Penetrating Peptides to Selectively Deliver Immune Modulatory Drugs. Pharmaceutics 13:3, pages 365.
Crossref
Crossref
Antonio Gonzalez-Lopez, Jaap Oostendorp, Thomas Koernicke, Tommaso Fadini, Ugo D'Oro, Sherryl Baker, Derek T. O’Hagan, Giuseppe Del Giudice, Emilio Siena, Oretta Finco & Duccio Medini. (2019) Adjuvant effect of TLR7 agonist adsorbed on aluminum hydroxide (AS37): A phase I randomized, dose escalation study of an AS37-adjuvanted meningococcal C conjugated vaccine. Clinical Immunology 209, pages 108275.
Crossref
Crossref
Philip J. Bergman. (2019) Cancer Immunotherapies. Veterinary Clinics of North America: Small Animal Practice 49:5, pages 881-902.
Crossref
Crossref
Cheryl Lai-Lai Chiang & Lana E. Kandalaft. (2018) In vivo cancer vaccination: Which dendritic cells to target and how?. Cancer Treatment Reviews 71, pages 88-101.
Crossref
Crossref
Santiswarup Singha, Kun Shao, Kristofor K. Ellestad, Yang Yang & Pere Santamaria. (2018) Nanoparticles for Immune Stimulation Against Infection, Cancer, and Autoimmunity. ACS Nano 12:11, pages 10621-10635.
Crossref
Crossref
Yun Xia, Yonghua Xie, Zhengsen Yu, Hongying Xiao, Guimei Jiang, Xiaoying Zhou, Yunyun Yang, Xin Li, Meng Zhao, Liping Li, Mingke Zheng, Shuai Han, Zhaoyun Zong, Xianbin Meng, Haiteng Deng, Huahu Ye, Yunzhi Fa, Haitao Wu, Eric Oldfield, Xiaoyu Hu, Wanli Liu, Yan Shi & Yonghui Zhang. (2018) The Mevalonate Pathway Is a Druggable Target for Vaccine Adjuvant Discovery. Cell 175:4, pages 1059-1073.e21.
Crossref
Crossref
Matthew D. Morin, Ying Wang, Brian T. Jones, Yuto Mifune, Lijing Su, Hexin Shi, Eva Marie Y. Moresco, Hong Zhang, Bruce Beutler & Dale L. Boger. (2018) Diprovocims: A New and Exceptionally Potent Class of Toll-like Receptor Agonists. Journal of the American Chemical Society 140:43, pages 14440-14454.
Crossref
Crossref
Philip J. Bergman. (2018) Veterinary Oncology Immunotherapies. Veterinary Clinics of North America: Small Animal Practice 48:2, pages 257-277.
Crossref
Crossref
V Mett, E A Komarova, K Greene, I Bespalov, C Brackett, B Gillard, A S Gleiberman, I A Toshkov, S Aygün-Sunar, C Johnson, E Karasik, M Bapardekar-Nair, O V Kurnasov, A L Osterman, P S Stanhope-Baker, C Morrison, M T Moser, B A Foster & A V Gudkov. (2017) Mobilan: a recombinant adenovirus carrying Toll-like receptor 5 self-activating cassette for cancer immunotherapy. Oncogene 37:4, pages 439-449.
Crossref
Crossref
Satheesha Avunje & Sung-Ju Jung. (2017) Poly (I:C) and imiquimod induced immune responses and their effects on the survival of olive flounder ( Paralichthys olivaceus ) from viral haemorrhagic septicaemia. Fish & Shellfish Immunology 71, pages 338-345.
Crossref
Crossref
C. Buonsanti & U. D'Oro. 2017. Immunopotentiators in Modern Vaccines. Immunopotentiators in Modern Vaccines
85
104
.
Matthew D. Morin, Ying Wang, Brian T. Jones, Lijing Su, Murali M. R. P. Surakattula, Michael Berger, Hua Huang, Elliot K. Beutler, Hong Zhang, Bruce Beutler & Dale L. Boger. (2016) Discovery and Structure–Activity Relationships of the Neoseptins: A New Class of Toll-like Receptor-4 (TLR4) Agonists. Journal of Medicinal Chemistry 59:10, pages 4812-4830.
Crossref
Crossref
Michael S. Ball, Emilie P. Shipman, Hyunjung Kim, Karen T. Liby & Patricia A. Pioli. (2016) CDDO-Me Redirects Activation of Breast Tumor Associated Macrophages. PLOS ONE 11:2, pages e0149600.
Crossref
Crossref
Dimitrios Papakostas & Eggert Stockfleth. (2015) Topical treatment of basal cell carcinoma with the immune response modifier imiquimod. Future Oncology 11:22, pages 2985-2990.
Crossref
Crossref
Tom Y.-H. WuManmohan SinghAndrew T. MillerEnnio De GregorioFrancesco DoroUgo D’OroDavid A. G. SkibinskiM. Lamine MbowSimone BufaliAnn E. HermanAlex CortezYongkai LiBishnu P. NayakElaine TrittoChristophe M. FilippiGillis R. OttenLuis A. BritoElisabetta MonaciChun LiSusanna ApreaSara ValentiniSamuele CalabrόDonatello LaeraBrunella BrunelliElena CaproniPadma MalyalaRekha G. PanchalTravis K. WarrenSina BavariDerek T. O’HaganMichael P. CookeNicholas M. Valiante. (2014) Rational design of small molecules as vaccine adjuvants. Science Translational Medicine 6:263.
Crossref
Crossref
Euna Yoo, Deepak B. Salunke, Diptesh Sil, Xiaoqiang Guo, Alex C. D. Salyer, Alec R. Hermanson, Manoj Kumar, Subbalakshmi S. Malladi, Rajalakshmi Balakrishna, Ward H. Thompson, Hiromi Tanji, Umeharu Ohto, Toshiyuki Shimizu & Sunil A. David. (2014) Determinants of Activity at Human Toll-like Receptors 7 and 8: Quantitative Structure–Activity Relationship (QSAR) of Diverse Heterocyclic Scaffolds. Journal of Medicinal Chemistry 57:19, pages 7955-7970.
Crossref
Crossref
Philip J. Bergman. (2014) Immunotherapy in Veterinary Oncology. Veterinary Clinics of North America: Small Animal Practice 44:5, pages 925-939.
Crossref
Crossref
K Zeljic, G Supic, N Jovic, R Kozomara, M Brankovic‐Magic, M Obrenovic & Z Magic. (2013) Association of TLR2, TLR3, TLR4 and CD14 genes polymorphisms with oral cancer risk and survival. Oral Diseases 20:4, pages 416-424.
Crossref
Crossref
Mohamed L. Salem. 2014. Cancer Vaccines. Cancer Vaccines
479
503
.
Sandro Goruppi & G. Paolo Dotto. (2013) Mesenchymal stroma: primary determinant and therapeutic target for epithelial cancer. Trends in Cell Biology 23:12, pages 593-602.
Crossref
Crossref
Tobias Kamphuis, Toon Stegmann, Tjarko Meijerhof, Jan Wilschut & Aalzen de Haan. (2013) A virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A provides protection against viral challenge without priming for enhanced disease in cotton rats. Influenza and Other Respiratory Viruses 7:6, pages 1227-1236.
Crossref
Crossref
Z G Fridlender, A Jassar, I Mishalian, L-CS Wang, V Kapoor, G Cheng, J Sun, S Singhal, L Levy & S M Albelda. (2013) Using macrophage activation to augment immunotherapy of established tumours. British Journal of Cancer 108:6, pages 1288-1297.
Crossref
Crossref
Saskia Stier, Claudia Maletzki, Ulrike Klier & Michael Linnebacher. (2013) Combinations of TLR Ligands: A Promising Approach in Cancer Immunotherapy. Clinical and Developmental Immunology 2013, pages 1-14.
Crossref
Crossref
Peter L. Stern, Sjoerd H. van der Burg, Ian N. Hampson, Thomas R. Broker, Alison Fiander, Charles J. Lacey, Henry C. Kitchener & Mark H. Einstein. (2012) Therapy of Human Papillomavirus-Related Disease. Vaccine 30, pages F71-F82.
Crossref
Crossref
David N. NguyenKerry P. MahonGhania Chikh, Phillip Kim, Hattie ChungAlain P. Vicari, Kevin T. LoveMichael GoldbergSteve ChenArthur M. Krieg, Jianzhu ChenRobert Langer & Daniel G. Anderson. (2012) Lipid-derived nanoparticles for immunostimulatory RNA adjuvant delivery. Proceedings of the National Academy of Sciences 109:14.
Crossref
Crossref
Giel R. Gaajetaan, Cathrien A. Bruggeman & Frank R Stassen. (2011) The type I interferon response during viral infections: a “SWOT” analysis. Reviews in Medical Virology 22:2, pages 122-137.
Crossref
Crossref
Valerie Chew, Han Chong Toh & Jean-Pierre Abastado. (2012) Immune Microenvironment in Tumor Progression: Characteristics and Challenges for Therapy. Journal of Oncology 2012, pages 1-10.
Crossref
Crossref
Şefik Ş. Alkan. 2012. Development of Novel Vaccines. Development of Novel Vaccines
1
26
.
Albert Gutierrez, Bonnie K. Arendt, Renee C. Tschumper, Neil E. Kay, Clive S. Zent & Diane F. Jelinek. (2011) Differentiation of Chronic Lymphocytic Leukemia B Cells into Immunoglobulin Secreting Cells Decreases LEF-1 Expression. PLoS ONE 6:10, pages e26056.
Crossref
Crossref
Céline Robert-Tissot, Vera L. Rüegger, Valentino Cattori, Marina L. Meli, Barbara Riond, Maria Alice Gomes-Keller, Andrea Vögtlin, Burghardt Wittig, Christiane Juhls, Regina Hofmann-Lehmann & Hans Lutz. (2011) The innate antiviral immune system of the cat: Molecular tools for the measurement of its state of activation. Veterinary Immunology and Immunopathology 143:3-4, pages 269-281.
Crossref
Crossref
Rosalinda Sorrentino, Silvana Morello, Maria Grazia Giordano, Claudio Arra, Piera Maiolino, Ian M. Adcock & Aldo Pinto. (2011) CpG-ODN increases the release of VEGF in a mouse model of lung carcinoma. International Journal of Cancer 128:12, pages 2815-2822.
Crossref
Crossref
Rosalinda Sorrentino, Silvana Morello, Giovanni Forte, Antonella Montinaro, Genoveffa De Vita, Antonio Luciano, Giuseppe Palma, Claudio Arra, Piera Maiolino, Ian M. Adcock & Aldo Pinto. (2011) B Cells Contribute to the Antitumor Activity of CpG-Oligodeoxynucleotide in a Mouse Model of Metastatic Lung Carcinoma. American Journal of Respiratory and Critical Care Medicine 183:10, pages 1369-1379.
Crossref
Crossref
S. Daayana, U. Winters, P. L. Stern & H. C. Kitchener. (2020) Clinical and immunological response to photodynamic therapy in the treatment of vulval intraepithelial neoplasia. Photochemical & Photobiological Sciences 10:5, pages 802-809.
Crossref
Crossref
J L Ebersole, M J Steffen, S C Holt, L Kesavalu, L Chu & D Cappelli. (2010) Systemic inflammatory responses in progressing periodontitis during pregnancy in a baboon model. Clinical and Experimental Immunology 162:3, pages 550-559.
Crossref
Crossref
Rosalinda Sorrentino, Silvana Morello, Antonio Luciano, Timothy R. Crother, Piera Maiolino, Eduardo Bonavita, Claudio Arra, Ian M. Adcock, Moshe Arditi & Aldo Pinto. (2010) Plasmacytoid Dendritic Cells Alter the Antitumor Activity of CpG-Oligodeoxynucleotides in a Mouse Model of Lung Carcinoma. The Journal of Immunology 185:8, pages 4641-4650.
Crossref
Crossref
Sacha Gnjatic, Nikhil B. Sawhney & Nina Bhardwaj. (2010) Toll-Like Receptor Agonists. The Cancer Journal 16:4, pages 382-391.
Crossref
Crossref
Philip J. Bergman. (2010) Cancer Immunotherapy. Veterinary Clinics of North America: Small Animal Practice 40:3, pages 507-518.
Crossref
Crossref
Chris L McGowinRichard B Pyles. (2010) Mucosal treatments for herpes simplex virus: insights on targeted immunoprophylaxis and therapy. Future Microbiology 5:1, pages 15-22.
Crossref
Crossref
M Mahto, M Nathan & C O'Mahony. (2010) More than a decade on: review of the use of imiquimod in lower anogenital intraepithelial neoplasia. International Journal of STD & AIDS 21:1, pages 8-16.
Crossref
Crossref
David Koos, Steven F. Josephs, Doru T Alexandrescu, Ray Chun-Fai Chan, Famela Ramos, Vladimir Bogin, Vincent Gammill, Constantin A. Dasanu, Rosalia De Necochea-Campion, Neil H. Riordan & Ewa Carrier. (2010) Tumor vaccines in 2010: Need for integration. Cellular Immunology 263:2, pages 138-147.
Crossref
Crossref
Mohamed L. Salem, Maha EL-Demellawy & Abdel Raouf Abou El-Azm. (2010) The potential use of Toll-like receptor agonists to restore the dysfunctional immunity induced by hepatitis C virus. Cellular Immunology 262:2, pages 96-104.
Crossref
Crossref
Lajos Kemény. 2009. Non-Surgical Treatment of Keratinocyte Skin Cancer. Non-Surgical Treatment of Keratinocyte Skin Cancer
123
132
.
Enrique Espinosa & César Gómez Raposo. 2010. Macromolecular Anticancer Therapeutics. Macromolecular Anticancer Therapeutics
3
35
.
Stephanie KadowBettina JuxStefanie ChmillCharlotte Esser. (2009) Small molecules as friends and foes of the immune system. Future Medicinal Chemistry 1:9, pages 1583-1591.
Crossref
Crossref
Yanal M. Murad & Timothy M. Clay. (2009) CpG Oligodeoxyneucleotides as TLR9 Agonists. BioDrugs 23:6, pages 361-375.
Crossref
Crossref
Jayalakshmi Krishnan, Gwang Lee & Sangdun Choi. (2009) Drugs targeting toll-like receptors. Archives of Pharmacal Research 32:11.
Crossref
Crossref
Jincun Zhao, Jingxian Zhao, Nico Van Rooijen & Stanley Perlman. (2009) Evasion by Stealth: Inefficient Immune Activation Underlies Poor T Cell Response and Severe Disease in SARS-CoV-Infected Mice. PLoS Pathogens 5:10, pages e1000636.
Crossref
Crossref
Philip J. Bergman. (2009) Cancer Immunotherapy. Topics in Companion Animal Medicine 24:3, pages 130-136.
Crossref
Crossref
Thiruma V. Arumugam, Eitan Okun, Sung-Chun Tang, John Thundyil, Stephen M. Taylor & Trent M. Woodruff. (2009) TOLL-LIKE RECEPTORS IN ISCHEMIA-REPERFUSION INJURY. Shock 32:1, pages 4-16.
Crossref
Crossref
E. Smit, H.M. Oberholzer & E. Pretorius. (2009) A review of immunomodulators with reference to Canova®. Homeopathy 98:3, pages 169-176.
Crossref
Crossref
C. Guiducci, R. L. Coffman & F. J. Barrat. (2009) Signalling pathways leading to IFN-α production in human plasmacytoid dendritic cell and the possible use of agonists or antagonists of TLR7 and TLR9 in clinical indications. Journal of Internal Medicine 265:1, pages 43-57.
Crossref
Crossref